Trials / Recruiting
RecruitingNCT07456878
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FET-PET/MRI | Patients will undergo PET/MR scan after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET) |
Timeline
- Start date
- 2026-01-08
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-03-09
- Last updated
- 2026-03-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07456878. Inclusion in this directory is not an endorsement.